Seres Therapeutics, Inc. — 2015 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2015; quarterly data below includes the fourth quarter. Seres is a development-stage microbiome therapeutics company with no product revenue and no approved products.
Business context
The company is developing Ecobiotic microbiome therapeutics intended to restore disrupted gut microbiomes. Lead candidate SER-109 targets recurrent Clostridium difficile infection (CDI). Other programs include SER-262 for prevention of initial CDI recurrence, SER-287 for ulcerative colitis, and earlier-stage SER-155 for infection-related risks in transplant recipients. The company reported 86 full-time employees at year-end.
Financial performance and position
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $38.1 million | $10.7 million |
| General and administrative expense | $16.8 million | $4.4 million |
| Total operating expenses / operating loss | $54.9 million | $15.1 million |
| Net loss | $54.8 million | $16.7 million |
| Net loss per share, basic and diluted | $2.33 | $2.67 |
| Cash used in operating activities | $40.8 million | $10.4 million |
At December 31, 2015, cash and cash equivalents were $73.9 million and short-term investments were $131.1 million, totaling $205.1 million. Working capital was $196.7 million; total assets were $216.9 million, total liabilities $11.5 million, and stockholders’ equity $205.4 million. The company had no debt at year-end after repaying its Comerica loan in September. No meaningful revenue or profit margin exists because the company had no revenue.
Fourth-quarter 2015 operating expenses were $19.8 million and net loss was $19.6 million, compared with $7.2 million and $8.2 million, respectively, in fourth-quarter 2014.
Material changes versus prior periods
- Annual net loss rose to $54.8 million from $16.7 million in 2014, primarily as research and development expanded; R&D expense increased by $27.4 million.
- Cash used in operations increased to $40.8 million from $10.4 million. The company also invested in short-term securities and property and equipment.
- The July 2015 IPO generated approximately $139.3 million in net proceeds. Preferred shares converted into common shares, and the company repaid its remaining loan balance.
- Stock-based compensation increased to $9.7 million from $2.1 million.
Outlook, developments, and risks
- Clinical plans: SER-109 Phase 2 results were expected in mid-2016, with a Phase 3 start planned for the second half of 2016, subject to results and FDA discussions. The company planned to begin SER-262 clinical testing in mid-2016. SER-287 Phase 1b began in December 2015.
- SER-109 early evidence: In an open-label Phase 1b/2 study of 30 patients, 26 (87%) met the defined eight-week recurrence endpoint and 29 (97%) achieved clinical cure, defined as no CDI requiring antibiotics during that period. The small, open-label study is not confirmatory evidence of efficacy; the controlled Phase 2 study was ongoing.
- Nestec collaboration, subsequent event: In January 2016, Seres licensed specified CDI and IBD products outside the United States and Canada to Nestec Ltd. The company received a $120 million upfront payment in February 2016, after the reporting date. Potential payments include up to $660 million in development and regulatory milestones, up to $1.125 billion in commercial milestones, and tiered royalties; these amounts are contingent and not assured. Seres retained North American rights and agreed to bear specified development costs. Nestec was identified as a related party through an affiliate shareholder.
- Liquidity outlook: Management said year-end cash, cash equivalents, and investments were expected to fund operations and capital spending “well into 2018.” A note to the financial statements instead said the balance would fund requirements through at least December 31, 2016. The filing does not reconcile these runway statements. The subsequent $120 million payment was received in February 2016.
- Commitments: A new Cambridge facility lease, signed in November 2015 but commencing in 2016, carries approximately $41.8 million of future minimum payments; it was excluded from the year-end contractual-obligations table because the lease had not commenced.
- Principal risks: The microbiome therapeutic approach is unproven, clinical outcomes may not be replicated, and FDA approval is uncertain. Further risks include trial enrollment and timing, manufacturing scale and quality, dependence on third parties and donor-derived material for SER-109, competition, intellectual-property challenges, reimbursement and future financing needs.
The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls were effective at a reasonable-assurance level; the filing did not include management’s assessment or auditor attestation of internal control over financial reporting because of the new-public-company transition period.
Important facts for investors to verify
- Reconcile the stated cash runway (“well into 2018” versus “through at least December 31, 2016”) and assess the effect of the February 2016 collaboration payment and development obligations.
- Review controlled Phase 2 SER-109 results, trial design and FDA feedback; confirm whether the planned Phase 3 timing and trial requirements changed.
- Track SER-262 and SER-287 trial initiation, enrollment, safety findings, and whether early results support further development.
- Assess the Nestec agreement’s milestone conditions, cost-sharing obligations, related-party governance, and the likelihood and timing of contingent payments and royalties.
- Monitor cash burn, manufacturing investment and the new lease commitments, as well as the company’s ability to fund development without further financing.